Filing Details

Accession Number:
0001209191-16-152058
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-11-25 21:32:25
Reporting Period:
2016-11-25
Filing Date:
2016-11-25
Accepted Time:
2016-11-25 21:32:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1479290 Revance Therapeutics Inc. RVNC Pharmaceutical Preparations (2834) 770551645
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1597583 Daniel L Browne C/O Revance Therapeutics, Inc.
7555 Gateway Boulevard
Newark CA 94560
Ceo And President Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-11-25 11,178 $17.86 208,449 No 4 S Direct
Common Stock Disposition 2016-11-25 822 $18.70 207,627 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 409 Indirect See footnote
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan originally adopted by Mr. Browne on December 7, 2015.
  2. This sale was scheduled under Mr. Browne's Rule 10b5-1 trading plan to defray Mr. Browne's tax expense relating to a Section 83(b) tax election in 2015.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $18.25. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.